Skip to main content

Table 1 Clinical characteristics of study participants (ELISA)

From: Impaired activation of STAT5 upon IL-2 stimulation in Tregs and elevated sIL-2R in Sjögren’s syndrome

  Healthy Non-severe Severe p-value
n 49 42 54 -
Age (years) 50.6±8.3 54.1±17.8 58.3±15.3 0.26
Sex (% female) 100% 100% 100% NA
Duration from onset (years) - 8.1±10.4a 12.4±13.8b 0.22
Duration from diagnosis (years) - 5.7±7.4c 8.7±7.7d 0.092
BMI - 25.7±4.3e 25.5±5.5f 0.59
Stimulated salivary flow rate - 7.0±3.3 ml/5 min 1.8±0.8 ml/5 min < 2.2 × 10-16
Schirmer right (mm/5 min) - 8.1±10.5g 6.3±9.0d 0.49
Schirmer left (mm/5 min) - 9.4±11.3g 6.9±9.6d 0.36
Anti-SSA - 27/73.0%h 35/74.5%i 0.88
Anti-SSB - 8/21.6%h 14/29.8%i 0.40
Seropositive (SSA and/or SSB) - 27/73.0%h 35/74.5%i 0.88
cDMARD - 11/32.4%e 10/24.4%j 0.21
bDMARD (anti-TNF) - 0k 0k NA
Glucocorticoid - 4/11.8%e 2/5.0%l 0.30
Cyclosporine eye drops - 6/27.3%m 725.9%n 0.93
Oral pilocarpine - 3/14.3%o 4/16%p 0.89
Natural tears - 6/25%q 10/38.5%r 0.32
Angina pectoris - 1r 0l 0.23
Autoimmune gastritis - 0r 1s 0.43
Autoimmune thyroid disease - 1j 4t 0.27
Proteinuria - 0p 3u 0.16
Hematuria - 0p 1g 0.42
Gynaecologic manifestation - 1p 2s 0.85
Non-specific interstitial pneumonia - 0q 1h 0.44
Fibromyalgia - 0q 2s 0.27
Anemia - 2p 3s 0.98
Leukopenia - 1p 3s 0.57
Neutropenia - 1p 2s 0.85
Thrombocytopenia - 0p 1s 0.44
Cancer - 1p 1u 0.78
Sclerosing cholangitis - 0p 1u 0.44
Psoriasis - 1j 1t 0.88
Other autoimmune diseases - 1j 1t 0.88
  1. Values for continuous variables are presented in mean ± SD. Mann-Whitney U test was used in the comparison between non-severe and severe patients
  2. an=20, bn=19, cn=36, dn=43, en=34, fn=42, gn=35, hn=37, in=47, jn=41, kn=17, ln=40, mn=22, nn=27, on=21, pn=25, qn=24, rn=26, sn=39, tn=52, un=38